ICER Report Dampens Prospects for Cystic Fibrosis Treatment

If health plans heed a new report from the Institute for Clinical and Economic Review, patients with few options to treat their cystic fibrosis may soon have fewer still.


In its recent assessment, ICER finds innovative cystic fibrosis drugs called CFTR modulator therapies too expensive. The therapies are the first medication to address the underlying cause of cystic fibrosis, while past treatments addressed only the disease’s symptoms. CFTR modulator therapies don’t work for every patient, but they are life changing for those who can use them.

Read more